WEGOVY Novo Nordisk Pharmaceuticals Pty Ltd
Product name
WEGOVY
Accepted date
Apr-2025
Active ingredients
Semaglutide
Proposed indication
Wegovy (semaglutide) is for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults, where there is also evidence of liver scarring. MASH is a disease where fat accumulation in the liver leads to inflammation and damage to liver cells.
Application type
C (new indication)
Publication date
Apr-2025
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.